← Eichor
Study identifier: NCT07739160 Synced from ClinicalTrials.gov · July 31, 2026
● Not Yet Recruiting

The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients

Condition: Acute Ischemic Stroke  ·  Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

PhasePhase 2
Planned participants340
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).

This description comes directly from the study's public registry record.

Talk to the study team

Jiawen Xu  ·  +86 19921874134  ·  jiawen.xu.jx130@hengrui.com

Xiao Chen  ·  +86 18861359350  ·  xiao.chen.xc1@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan Hospital, Capital Medical UniversityBeijing, Beijing Municipality, China

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07739160